Statements (28)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:chemical_compound
antineoplastic agent |
| gptkbp:administered_via |
oral route
|
| gptkbp:approvalYear |
1999
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
L01AX03
|
| gptkbp:CASNumber |
85622-93-1
|
| gptkbp:discoveredBy |
gptkb:Malcolm_Stevens
|
| gptkbp:drugClass |
alkylating agents
imidazotetrazines |
| gptkbp:eliminationHalfLife |
1.8 hours
|
| gptkbp:hasMolecularFormula |
C6H6N6O2
|
| https://www.w3.org/2000/01/rdf-schema#label |
Temozolomideum
|
| gptkbp:IUPACName |
gptkb:3,4-dihydro-3-methyl-4-oxoimidazo[5,1-d]-as-tetrazine-8-carboxamide
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:marketedAs |
gptkb:Temodal
gptkb:Temodar |
| gptkbp:mechanismOfAction |
DNA methylation
antineoplastic agent |
| gptkbp:metabolism |
liver
|
| gptkbp:sideEffect |
nausea
vomiting fatigue myelosuppression |
| gptkbp:usedFor |
gptkb:glioblastoma_multiforme
gptkb:anaplastic_astrocytoma |
| gptkbp:bfsParent |
gptkb:C10483
|
| gptkbp:bfsLayer |
7
|